US 12,290,595 B2
Implantable depots for the controlled release of therapeutic agents
Karun D. Naga, Los Altos, CA (US); Hanson S. Gifford, III, Woodside, CA (US); Stephen W. Boyd, San Francisco, CA (US); Patrick H. Ruane, El Dorado Hills, CA (US); Jackie Joe Hancock, Albany, CA (US); Michael Feldstein, San Francisco, CA (US); Koon Kiat Teu, Singapore (SG); Honglei Wang, Singapore (SG); Jingnan Luo, Singapore (SG); and Daniel Boon Lim Seet, Singapore (SG)
Assigned to Foundry Therapeutics, Inc., Menlo Park, CA (US)
Filed by Foundry Therapeutics, Inc., Menlo Park, CA (US)
Filed on Mar. 28, 2024, as Appl. No. 18/620,329.
Application 18/620,329 is a continuation of application No. 17/454,320, filed on Nov. 10, 2021, granted, now 11,969,500.
Application 17/454,320 is a continuation of application No. 17/248,949, filed on Feb. 15, 2021, granted, now 11,224,570, issued on Jan. 18, 2022.
Application 17/248,949 is a continuation of application No. 16/840,215, filed on Apr. 3, 2020, granted, now 11,202,754, issued on Dec. 21, 2021.
Application 16/840,215 is a continuation of application No. PCT/US2018/054777, filed on Oct. 6, 2018.
Claims priority of provisional application 62/723,478, filed on Aug. 28, 2018.
Claims priority of provisional application 62/670,721, filed on May 12, 2018.
Claims priority of provisional application 62/640,571, filed on Mar. 8, 2018.
Claims priority of provisional application 62/569,349, filed on Oct. 6, 2017.
Prior Publication US 2024/0315957 A1, Sep. 26, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/70 (2006.01); A61K 9/00 (2006.01); A61K 31/445 (2006.01); A61K 47/34 (2017.01)
CPC A61K 9/0024 (2013.01) [A61K 31/445 (2013.01); A61K 47/34 (2013.01)] 20 Claims
 
1. A system for treating postoperative pain, the system comprising:
one or more depots configured to be implanted at a treatment site, wherein the one or more depots each comprise:
a therapeutic region comprising a biodegradable polymer and an analgesic, the therapeutic region having a first surface, a second surface opposite the first surface, and an exposed sidewall between the first and second surfaces;
a first control region covering the first surface of the therapeutic region and having a thickness no greater than 1/50 of a thickness of the therapeutic region, the first control region comprising a biodegradable polymer; and
a second control region covering the second surface of the therapeutic region and having a thickness no greater than 1/50 of the thickness of the therapeutic region, the second control region comprising a biodegradable polymer,
wherein the analgesic constitutes at least 50% of a total weight of the depot, and
wherein, when the one or more depots are implanted at the treatment site, the one or more depots are configured to release the analgesic at the treatment site for a release duration of no less than 14 days.